Table 1.

Tumor characteristics after MK-0457-based therapy

Cell lineTreatmentNodules, median no. (range)P (vs control)
HeyA8Control8.5 (1-31)
MK-04573 (1-7)0.01
Docetaxel3 (2-10)0.04
MK-0457/docetaxel2 (1-6)0.01
SKOV3ip1Control22 (3-60)
MK-04575 (2-9)0.006
Docetaxel4.5 (2-40)0.02
MK-0457/docetaxel2 (1-9)0.002
HeyA8-MDRControl10 (2-21)
MK-04574 (2-9)0.02
Docetaxel11 (2-30)NS
MK-0457/docetaxel4.5 (1-7)0.003
A2780-CP20Control48 (4-63)
MK-04573.5 (0-16)0.01
Cisplatin21 (7-36)NS
MK-0457/cisplatin2 (0-13)0.008